Methofill (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, stopping the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This inhibition particularly affects rapidly dividing cells, such as immune cells and malignant cells, thereby reducing inflammation in autoimmune diseases and limiting tumor growth.

The dose of Methofill is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Only a qualified healthcare professional should determine the appropriate dosing schedule and any necessary adjustments.

Methofill is classified as Pregnancy Category X because it is known to cause fetal harm and birth defects. It should not be used by pregnant women, and effective contraception is required for both men and women of child‑bearing potential. Breastfeeding is also contraindicated, as methotrexate can be excreted in milk.

To request Methofill, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Methofill (methotrexate) is a conventional synthetic DMARD and is often the first‑line therapy for rheumatoid arthritis due to its proven efficacy and cost‑effectiveness. Biologic DMARDs such as etanercept or adalimumab target specific cytokines and may be used when methotrexate alone is insufficient, but they are generally more expensive and require injection or infusion.

Methofill should be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary temperature excursions occur, consult the supplier before use.

Methofill is supplied for subcutaneous injection. A healthcare professional prepares the dose using a sterile syringe and injects it into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique. Patients should be trained on proper injection sites and rotation to minimize local reactions.

The most serious adverse events include severe liver toxicity, pulmonary fibrosis or interstitial pneumonitis, profound bone‑marrow suppression leading to pancytopenia, and life‑threatening infections. Early detection through regular laboratory monitoring and prompt reporting of respiratory or hepatic symptoms are essential to mitigate these risks.

Methofill is contraindicated in pregnant or breastfeeding individuals, patients with severe hepatic or renal impairment, those with active infections, and individuals with known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for patients with pre‑existing lung disease.